Show simple item record

dc.contributor.authorPayne, Hen_US
dc.contributor.authorAdamson, Aen_US
dc.contributor.authorBahl, Aen_US
dc.contributor.authorBorwell, Jen_US
dc.contributor.authorDodds, Den_US
dc.contributor.authorHeath, Cen_US
dc.contributor.authorHuddart, Ren_US
dc.contributor.authorMcMenemin, Ren_US
dc.contributor.authorPatel, Pen_US
dc.contributor.authorPeters, JLen_US
dc.contributor.authorThompson, Aen_US
dc.date.accessioned2018-07-23T13:20:41Z
dc.date.issued2013-11en_US
dc.identifier.citationBJU international, 2013, 112 (7), pp. 885 - 897en_US
dc.identifier.issn1464-4096en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2114
dc.identifier.eissn1464-410Xen_US
dc.identifier.doi10.1111/bju.12291en_US
dc.description.abstract• To review the published data on predisposing risk factors for cancer treatment-induced haemorrhagic cystitis (HC) and the evidence for the different preventive and therapeutic measures that have been used in order to help clinicians optimally define and manage this potentially serious condition. • Despite recognition that HC can be a significant complication of cancer treatment, there is currently a lack of UK-led guidelines available on how it should optimally be defined and managed. • A systematic literature review was undertaken to evaluate the evidence for preventative measures and treatment options in the management of cancer treatment-induced HC. • There is a wide range of reported incidence due to several factors including variability in study design and quality, the type of causal agent, the grading of bleeding, and discrepancies in definition criteria. • The most frequently reported causal factors are radiotherapy to the pelvic area, where HC has been reported in up to 20% of patients, and treatment with cyclophosphamide and bacillus Calmette-Guérin, where the incidence has been reported as up to 30%. • Mesna (2-mercaptoethane sodium sulphonate), hyperhydration and bladder irrigation have been the most frequently used prophylactic measures to prevent treatment-related cystitis, but are not always effective. • Cranberry juice is widely cited as a preventative measure and sodium pentosanpolysulphate as a treatment, although the evidence for both is very limited. • The best evidence exists for intravesical hyaluronic acid as an effective preventative and active treatment, and for hyperbaric oxygen as an equally effective treatment option. • The lack of robust data and variability in treatment strategies used highlights the need for further research, as well as best practice guidance and consensus on the management of HC.en_US
dc.formatPrinten_US
dc.format.extent885 - 897en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectCystitisen_US
dc.subjectHemorrhageen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectRadiotherapyen_US
dc.subjectIncidenceen_US
dc.titleChemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges.en_US
dc.typeJournal Article
dcterms.dateAccepted2013-03-06en_US
rioxxterms.versionofrecord10.1111/bju.12291en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
rioxxterms.licenseref.startdate2013-11en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBJU internationalen_US
pubs.issue7en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublisheden_US
pubs.volume112en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/